X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GT-2108
Therapeutic Area: Gastroenterology Product Name: GT-2108
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Financing June 30, 2021
Details:
Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GT-2108
Therapeutic Area: Gastroenterology Product Name: GT-2108
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 19, 2021
Details:
The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
